Uterine fibroids segment
According to MarketScan and Truven Health Analytics, approximately 9 million women in the US seek therapy for symptoms related to uterine fibroids (or UF). While a significant percentage of women suffers from UF, to date, there haven’t been effective pharmacological treatment options available on the market. Neurocrine Biosciences’ (NBIX) and AbbVie’s (ABBV) Elagolix can capitalize on this opportunity in the UF segment. To know more about treatment options for UF, please refer to Elagolix May Become a Leading Uterine Fibroids Drug.
If Elagolix is approved by regulatory authorities for UF, it could have a positive impact on share prices of Neurocrine Biosciences as well as those of the First Trust Health Care AlphaDEX Fund (FXH). Neurocrine Biosciences makes up about 0.44% of FXH’s total portfolio holdings.
Uterine fibroid phase 2b trial
The above diagram shows the design of the Phase 2b trial undertaken by AbbVie for evaluating the efficacy of Elagolix in the UF space. In this trial, a higher dosage of Elagolix is being given to the clinical subjects than that administered in the endometriosis trial. This is because these patients suffer from excessive bleeding due to UF. While higher dosages are required to control this bleeding, it may also have an adverse impact on the bone mineral density of women. To solve this problem, AbbVie has also developed an add-back therapy to go along with Elagolix. To know more about this clinical trial, please refer to Clinical Trial Data Shows Efficacy of Elagolix to Treat Uterine Fibroids.